GigaGen Receives NIH Grant to Develop Production Technology for Recombinant Intravenous Immunoglobulin

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, has been awarded a $3 million grant from the National Institutes of Health (NIH) to advance its next-generation plasma therapy for patients with immune deficiencies. GigaGen will use the funds to develop a natural repertoire antibody protein expression system, laying the foundation for a recombinant immunoglobulin (rIVIG) therapy for patients with primary immunodeficiency diseases (PI) that overcomes many of the limitations of current plasma-based IVIG options.

Read the full press release.